Erythropoietin (EOP) is a type of cytokine produced by regulative erythrocytes, it’s mainly used as replacement therapy for renal-failure or cancerous patients who’re taking kidney dialysis treatment, in order to cure anemia. To keep marrow continuously producing erythrocyte, patients have to decide the frequency of medication according to the half life of the drug’s intravital metabolism; in this aspect, developing long-acting EPO to reduce its medication frequency not only could help relieving patient’s pain, but also have profound economic meaning.

Novel long-acting Erythropoietin — Nova-EPO is developed by our proprietary protein engineering technology platform, its half life is about 40 hours, much longer than that of first generation’s EOP and Amgen’s long-acting EPO. In the anemia test by animal model, it’s confirmed that injecting Nova-EPO two weeks a time is enough to obtain excellent anti-anemia results. Comparative animal test of the first generation’s EPO and Amgen’s long-acting EPO confirmed that Nova-EPO not only have longer biological half life, but also is superior to Amgen’s long-acting EPO in anti-anemic activity.

EPO has a unique therapeutic effect and a clear clinical indication. There’s a close correlation between result of EPO’s animal test and result of human clinical application, that is, if it works on animals it will definitely work on human beings. The possibility of failure in clinical application is almost zero. Besides, clinical test is easy to implement and the testing indicators are easy to be inspected, thus the risk of developing novel long-acting EPO only exists in technology developing stage.